In the line of fire
With the safety of public health foremost in the minds, the move by Indian drug regulator to stop the manufacturing of the anti-obesity drug in the country seems to have to have gone down well in industry circles. However, it is the role donned by the American drug regulator that is causing a lot of heart-burn in the domestic pharmaceutical industry.
“Indian drug companies are deliberately being singled out and capital punishment reserved especially for them,” says an industry insider. Little wonder, their brushes with the drug regulators—in India as well as overseas—is something they would like to forget as early as possible.
India has about 75 USFDA approved plants and is one of the most dominant players in global exports of generic formulation and active pharmaceutical ingredients. In the Asian region, China comes a distant second with 22
Be the first to comment.